


A Figure S1. Antifungal agents used for specific *Candida* species. Agents prescribed by the primary team (A, C) and recommended by the Infectious Diseases team (B, D) from 2006-2010 and from 20011-2016. Antifungal agents prescribed by the primary team (C) and recommended by the Infectious Diseases team (D) from 2011-2016

NOTE. Other agents as initial therapy included micafungin + voriconazole + amphotericin B (1), amphotericin B + fluconazole (2), amphotericin B + voriconazole (1), voriconazole (1), posaconazole (1); as recommended per ID team included amphotericin B + fluconazole (2), amphotericin B + voriconazole (1), micafungin + fluconazole (1), micafungin + posaconazole (1), micafungin + voriconazole + amphotericin B (1).



A Figure S2. Antifungals received at the time of breakthrough CBSI and species causing breakthrough. Other species were *C. kefyr* while on amphotericin B, and *C. guilliermondii* and *C. membranifaciens* while on azoles.